1. A game call apparatus comprising:
a mouthpiece including:
an air inlet opening;
an air outlet opening;
a mouthpiece air passageway connecting the air inlet opening and the air outlet opening;
an outer sound chamber including:
an air inlet opening;
an air exit opening;
an internal surface connecting the air inlet opening of the outer sound chamber and the air exit opening;
an inner sound chamber including:
an air inlet opening in communication with the air outlet opening of the mouthpiece;
an air outlet opening in communication with the air inlet opening of the outer sound chamber; and
an inner sound chamber air passageway connecting the air inlet opening of the inner sound chamber and the air outlet opening of the inner sound chamber, the inner sound chamber air passageway being in communication with the mouthpiece air passageway to permit air passage between the air inlet opening of the mouthpiece and the air exit opening of the outer sound chamber.
2. The game call apparatus of claim 1, further comprising a reed assembly disposed within the mouthpiece air passage.
3. The game call apparatus of claim 2, wherein the reed assembly includes:
a sounding board defining a trough through which air passes within the game call apparatus; and
a reed supported by the sounding board.
4. The game call apparatus of claim 3, wherein the reed assembly further includes a wedge, and the reed is supported between the sounding board and the wedge.
5. The game call apparatus of claim 1, wherein the inner sound chamber is removably mounted to the mouthpiece.
6. The game call apparatus of claim 1, wherein the outer sound chamber tapers inwardly and toward the air exit opening.
7. The game call apparatus of claim 1, wherein the air exit opening has a first cross-sectional area, the air outlet opening of the inner sound chamber has a second cross-sectional area, and the second cross-sectional area is larger than the first cross-sectional area.
8. The game call apparatus of claim 1, wherein the internal surface of the outer sound chamber defines an outer sound chamber air passageway from the air inlet opening of the inner sound chamber to the air exit opening.
9. A game call apparatus comprising:
a mouthpiece having an air inlet opening, an air outlet opening, and a mouthpiece air passageway through which air passes from the air inlet opening to the air outlet opening;
a reed assembly disposed within the mouthpiece air passageway and including a sounding board defining a trough through which air passes within the game call apparatus;
an inner sound chamber having an air inlet opening, an air outlet opening, and an inner sound chamber air passageway through which air passes from the air inlet opening of the inner sound chamber to the air outlet opening of the inner sound chamber, the inner sound chamber air passageway being in communication with the trough and the mouthpiece air passageway; and
an outer sound chamber in communication with the air outlet opening of the inner sound chamber, the outer sound chamber having an air exit opening through which air from the inner sound chamber air passageway escapes from the game call apparatus.
10. The game call apparatus of claim 9, wherein the reed assembly further includes a reed supported by the sounding board.
11. The game call apparatus of claim 10, wherein the reed assembly further includes a wedge, and the reed is supported between the sounding board and the wedge.
12. The game call apparatus of claim 11, wherein the sounding board and the wedge are directly supported by the inner sound chamber within the inner sound chamber air passageway.
13. The game call apparatus of claim 9, wherein the outer sound chamber includes an internal surface defining an outer sound chamber air passageway from the air inlet opening of the inner sound chamber to the air exit opening.
14. The game call apparatus of claim 13, wherein the inner sound chamber includes an air outlet end defining the air outlet opening of the inner sound chamber, the air outlet end including an outer surface, and further comprising an air space between the internal surface of the outer sound chamber and the outer surface of the inner sound chamber.
15. The game call apparatus of claim 9, wherein the inner sound chamber is removably mounted to the mouthpiece.
16. The game call apparatus of claim 9, wherein the outer sound chamber tapers inwardly and toward the air exit opening.
17. The game call apparatus of claim 16, wherein the air exit opening of the outer sound chamber has a first cross-sectional area, the air outlet opening of the inner sound chamber has a second cross-sectional area, and the second cross-sectional area is larger than the first cross-sectional area.
18. The game call apparatus of claim 9, wherein the mouthpiece includes an air outlet end defining the air outlet opening of the mouthpiece, the inner sound chamber includes an air inlet end defining the air inlet opening of the inner sound chamber, the air inlet end of the inner sound chamber is removably inserted in the mouthpiece air passageway, and the inner sound chamber extends away from the air outlet end of the mouthpiece.
19. The game call apparatus of claim 9, wherein the air exit opening of the outer sound chamber has a first cross-sectional area, the air outlet opening of the inner sound chamber has a second cross-sectional area, and the second cross-sectional area is larger than the first cross-sectional area.
20. A game call apparatus comprising:
a mouthpiece including:
an air inlet end;
an air outlet end having an axially extending portion defining an air outlet opening;
an outer sound chamber including:
a first end removably engaging the mouthpiece;
a second end extending away from the mouthpiece and having an air exit opening through which air escapes from the game call apparatus;
an inner sound chamber extending away from the mouthpiece and including:
an air inlet end removably engaging the mouthpiece; and
an air outlet end defining an air outlet opening in communication with the outer sound chamber.
21. The game call apparatus of claim 20, wherein the air outlet end of the mouthpiece includes:
an end surface;
an external surface;
a flange spaced apart from the end surface and extending radially outwardly from the external surface; and
wherein the first end of the outer sound chamber abuts the flange of the mouthpiece and includes an internal surface removably fitted over the external surface of the mouthpiece.
22. The game call apparatus of claim 20, wherein the air outlet end of the mouthpiece includes an internal section defining the air outlet opening of the mouthpiece, and the air inlet end of the inner sound chamber is removably inserted in the internal section of the mouthpiece.
23. The game call apparatus of claim 20, wherein the air outlet end of the inner sound chamber is disposed between the first end and the second end of the outer sound chamber.
24. The game call apparatus of claim 20, wherein the outer sound chamber tapers inwardly from the first end to the second end.
25. The game call apparatus of claim 20, further comprising a reed assembly including:
a sounding board defining a trough through which air passes within the game call apparatus, the sounding board being supported by the air inlet end of the inner sound chamber and extending into the mouthpiece; and
a reed supported by the sounding board.
26. The game call apparatus of claim 25, wherein the mouthpiece further includes an air passageway connecting the air inlet end and the air outlet end of the mouthpiece, the sounding board extending into the air passageway.
27. The game call apparatus of claim 25, wherein the reed assembly further includes a wedge, and the reed is supported between the sounding board and the wedge.
28. The game call apparatus of claim 27, wherein the outer sound chamber tapers inwardly from the first end to the second end.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I, or a pharmaceutically acceptable salt thereof,
wherein each R1 and each R2 and each R7 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, (C1-C6)alkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl, and (C3-C10)cycloalkyl; wherein said (C1-C6)alkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl, or (C3-C10)cycloalkyl are each independently optionally substituted with one, two, three or four R9;
w is 0, 1 or 2;
m is zero, one, two or three;
n is zero, one, two or three;
p is zero, one, two or three;
q is zero, one, two or three;
s is one and t is one; or one of s or t is one and the other of s or t is two;
R3 is hydrogen or (C1-C6)alkyl;
each R4 is independently selected from hydrogen, or (C1-C6)alkyl; wherein said (C1-C6)alkyl may be optionally substituted with one, two, three or four halogen, \u2014CN, or \u2014OR9;
or two R4 groups on the same carbon atom may be taken together to form an oxo (\u2550O) radical or a (C3-C6)spirocycloalkyl;
R5 is hydrogen, or (C1-C6)alkyl;
R6 is (C1-C6)alkyl-(C\u2550O)\u2014, (C1-C6)alkyl2N\u2014(C\u2550O)\u2014, (C1-C6)alkyl-SO2\u2014, (C3-C10)cycloalkyl-SO2\u2014, or (C1-C6)alkyl2N\u2014SO2\u2014; wherein said (C1-C6)alkyl moieties of said (C1-C6)alkyl2N\u2014(C\u2550O)\u2014 and (C1-C6)alkyl2N\u2014SO2\u2014 may optionally be taken together with the nitrogen atom to which they are attached to form a four to six membered heterocyclic ring;
R8 is independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl, and (C3-C10)cycloalkyl; wherein said (C1-C6)alkyl may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, \u2014CN, perfluoro(C1-C6)alkyl, hydroxy, amino, (C1-C6)alkylamino, (C1-C6)alkyl2amino, (C1-C6)alkoxy, perfluoro(C1-C6)alkoxy, HO\u2014(C\u2550O)\u2014, (C1-C6)alkyl-O\u2014(C\u2550O)\u2014, formyl, (C1-C6)alkyl-(C\u2550O)\u2014, H2N\u2014(C\u2550O)\u2014, (C1-C6)alkyl-(NH)\u2014(C\u2550O)\u2014, (C1-C6)alkyl2N\u2014(C\u2550O)\u2014, (C1-C6)alkyl-(C\u2550O)\u2014O\u2014, H(C\u2550O)\u2014NH\u2014, (C1-C6)alkyl(C\u2550O)\u2014NH\u2014, (C1-C6)alkyl(C\u2550O)\u2014N((C1-C6)alkyl)-, (C1-C6)alkyl-SO2\u2014, (C1-C6)alkyl-SO2\u2014NH\u2014, (C1-C6)alkyl-SO2\u2014N((C1-C6)alkyl)-, H2N\u2014SO2\u2014, (C1-C6)alkyl-NH\u2014SO2\u2014, and (C1-C6)alkyl2N\u2014SO2\u2014; wherein said (C1-C6)alkyl may be additionally optionally substituted with an optionally substituted (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl, or (C3-C10)cycloalkyl; wherein said optional substituents may be independently selected from one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF3, \u2014ON, (C1-C3)alkyl, (C1-C3)alkoxy, and amino; wherein each of said R8 (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl or (C3-C10)cycloalkyl substituents may be optionally additionally substituted with one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF3, \u2014CN, (C1-C3)alkyl, (C1-C3)alkoxy and amino;
each R9 is independently selected from the group consisting of halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R10, \u2014O\u2014(C\u2550O)\u2014R10, \u2014(NR10)\u2014(C\u2550O)\u2014R10, \u2014(C\u2550O)\u2014OR10, \u2014(C\u2550O)\u2014N(R10)2, \u2014OR10, \u2014O\u2014(C\u2550O)\u2014OR10, \u2014O\u2014(C\u2550O)\u2014N(R10)2, \u2014NO2, \u2014N(R10)2, \u2014(NR10)\u2014SO2\u2014R10, \u2014S(O)uR10, \u2014SO2\u2014N(R10)2;
R10 is independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl and (C3-C10)cycloalkyl; wherein said (C1-C6)alkyl may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, \u2014CN, perfluoro(C1-C6)alkyl, hydroxy, amino, (C1-C6)alkylamino, (C1-C6)alkyl2amino, (C1-C6)alkoxy, perfluoro(C1-C6)alkoxy, HO\u2014(C\u2550O)\u2014, (C1-C6)alkyl-O\u2014(C\u2550O)\u2014, formyl, (C1-C6)alkyl-(C\u2550O)\u2014, H2N\u2014(C\u2550O)\u2014, (C1-C6)alkyl-(NH)\u2014(C\u2550O)\u2014, (C1-C6)alkyl2N\u2014(C\u2550O)\u2014, (C1-C6)alkyl-(C\u2550O)\u2014O\u2014, H(C\u2550O)\u2014NH\u2014, (C1-C6)alkyl(C\u2550O)\u2014NH\u2014, (C1-C6)alkyl(C\u2550O)\u2014N((C1-C6)alkyl)-, (C1-C6)alkyl-SO2\u2014, (C1-C6)alkyl-SO2\u2014NH\u2014, (C1-C6)alkyl-SO2\u2014N((C1-C6)alkyl)-, H2N\u2014SO2\u2014, (C1-C6)alkyl-NH\u2014SO2\u2014, and (C1-C6)alkyl2N\u2014SO2\u2014; wherein said (C1-C6)alkyl may also be additionally optionally substituted with an optionally substituted (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl or (C3-C10)cycloalkyl; wherein said optional substituents may be independently selected from one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF3, \u2014CN, (C1-C3)alkyl, (C1-C3)alkoxy, and amino; wherein each of said R10 (C6-C10)aryl, (C1-C9)heteroaryl, (C1-C9)heterocycloalkyl, or (C3-C10)cycloalkyl substituents may be optionally additionally substituted with one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF3, \u2014CN, (C1-C3)alkyl, (C1-C3)alkoxy, and amino;
R11 is hydrogen or (C1-C6)alkyl;
ring \u201cA\u201d is (C6-C10)aryl, (C1-C9)heteroaryl, (C4-C10)cycloalkyl, or (C1-C9)heterocycloalkyl; wherein two of said R1 substituents on said (C4-C10)cycloalkyl and (C1-C9)heterocycloalkyl may optionally be attached to the same carbon atom and may optionally be taken together to be oxo;
ring \u201cB\u201d is (C6-C10)aryl, (C1-C9)heteroaryl, (C4-C10)cycloalkyl, or (C1-C9)heterocycloalkyl;
\u201cX\u201d is \u2014O\u2014 or >C(R4)2;
\u201cY\u201d is absent, >NR11, \u2014(NR11)\u2014(C\u2550O)\u2014, >C\u2550O, \u2014O\u2014 or >C(R7)2; and
\u201cZ\u201d is \u2014O\u2014, \u2014S\u2014, \u2014(S\u2550O)\u2014, or \u2014(SO2)\u2014.
2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is of Formula Ia:
3. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is of Formula Ib:
4. A compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein \u201cZ\u201d is \u2014O\u2014.
5. A compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein X is \u2014O\u2014.
6. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cA\u201d is phenyl.
7. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein ring \u201cA\u201d is phenyl; n is zero, one or two; R1 is selected from the group consisting of hydrogen, halogen, hydroxyl, \u2014CF3, \u2014ON, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
8. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cA\u201d is (C1-C9)heteroaryl; n is zero, one or two; and wherein R1 is selected from the group consisting of hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
9. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cA\u201d is (C1-C9)heterocycloalkyl; n is zero, one or two; and wherein R1 is selected from the group consisting of oxo, hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
10. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cA\u201d is (C4-C10)cycloalkyl; n is zero, one or two; and wherein R1 is selected from the group consisting of oxo, hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
11. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R1 is (C1-C6)alkoxy, (C1-C6)alkyl, cyano or halogen and is in the ortho or para position relative to Y.
12. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cB\u201d is phenyl; n is zero or one; R2 is hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, (NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
13. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cB\u201d is (C1-C9)heteroaryl; n is zero or one; and wherein R2 is hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
14. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cB\u201d is (C1-C9)heterocycloalkyl; n is zero or one; and wherein R2 is hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
15. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein ring \u201cB\u201d is (C4-C10)cycloalkyl; n is zero or one; and wherein R2 is hydrogen, halogen, hydroxyl, \u2014CF3, \u2014CN, \u2014(C\u2550O)R8, \u2014O\u2014(C\u2550O)\u2014R8, \u2014(NR8)\u2014(C\u2550O)\u2014R8, \u2014(C\u2550O)\u2014OR8, \u2014(C\u2550O)\u2014N(R8)2, \u2014OR8, \u2014O\u2014(C\u2550O)\u2014OR8, \u2014O\u2014(C\u2550O)\u2014N(R8)2, \u2014NO2, \u2014N(R8)2, \u2014(NR8)\u2014SO2\u2014R8, \u2014S(O)wR8, \u2014SO2\u2014N(R8)2, and (C1-C6)alkyl; wherein said (C1-C6)alkyl is optionally substituted with one, two, three or four R9.
16. A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R2 is (C1-C6)alkoxy, (C1-C6)alkyl, cyano or halogen.
17. A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen.
18. A compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen.
19. A compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein p is two and both R4 are taken together to form oxo.
20. A compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein p is two and each R4 is (C1-C6)alkyl.
21. A compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein q is zero.
22. A compound according to claim 21, or a pharmaceutically acceptable salt thereof, wherein Y is absent.
23. A compound according to claim 21, or a pharmaceutically acceptable salt thereof, wherein Y is \u2014O\u2014.
24. A compound according to claim 21, or a pharmaceutically acceptable salt thereof, wherein Y is >C(R7)2.
25. A compound according to claim 22, or a pharmaceutically acceptable salt thereof, wherein R6 is (C1-C5)alkyl-(C\u2550O)\u2014.
26. A compound according to claim 22, or a pharmaceutically acceptable salt thereof, wherein R6 is (C1-C2)alkyl2N\u2014(C\u2550O)\u2014, wherein said (C1-C2)alkyl moieties may optionally be taken together with the nitrogen atom to which they are attached to form a four to six membered heterocyclic ring.
27. A compound according to claim 22, or a pharmaceutically acceptable salt thereof, wherein R6 is (C1-C5)alkyl-SO2\u2014.
28. A compound according to claim 22, or a pharmaceutically acceptable salt thereof, wherein R6 is (C3-C5)cycloalkyl-SO2\u2014.
29. A compound according to claim 22, or a pharmaceutically acceptable salt thereof, wherein R6 is (C1-C2)alkyl2N\u2014SO2\u2014; wherein said (C1-C2)alkyl moieties may optionally be taken together with the nitrogen atom to which they are attached to form a four to six membered heterocyclic ring.
30. A compound that is:
N-{1-4-trans-({4-(isopropylsulfonyl)aminotetrahydrofuran-3-yl}oxy)phenylpyrrolidin-3-yl}acetamide;
N-(3S,4S)-4-(biphenyl-4-yloxy)tetrahydrofuran-3-ylpropane-2-sulfonamide;
N-{(3S,4S)-4-(2\u2032-cyanobiphenyl-4-yl)oxytetrahydrofuran-3-yl}propane-2-sulfonamide;
N-{(3S,4S)-4-4-(5-cyano-2-thienyl)phenoxytetrahydrofuran-3-yl}propane-2-sulfonamide;
N-{(1S,2R)-2-(2\u2032-cyanobiphenyl-4-yl)oxycyclopentyl}propane-2-sulfonamide;
N-{(1S,2R)-2-4-(5-cyano-2-thienyl)phenoxycyclopentyl}propane-2-sulfonamide;
N-{(1S,2R)-2-(2\u2032-cyanobiphenyl-4-yl)oxycyclohexyl}propane-2-sulfonamide;
cis-N-4-(4-pyridin-3-ylphenoxy)tetrahydrofuran-3-ylpropane-2-sulfonamide;
cis-N-{4-4-(2-thienyl)phenoxytetrahydrofuran-3-yl}propane-2-sulfonamide;
N-{(3S,4S)-4-(2\u2032-cyano-4\u2032-fluorobiphenyl-4-yl)oxytetrahydrofuran-3-yl}propane-2-sulfonamide;
N-{(3S,4S)-4-(4\u2032-fluorobiphenyl-4-yl)oxytetrahydrofuran-3-yl}propane-2-sulfonamide;
N-{(3S,4S)-4-(2\u2032-ethoxy-4\u2032-fluorobiphenyl-4-yl)oxytetrahydrofuran-3-yl}propane-2-sulfonamide;
cis-N-4-{6-(5-cyano-2-thienyl)pyridin-3-yloxy}tetrahydrofuran-3-ylpropane-2-sulfonamide;
cis-N-{4-4-(3-thienyl)phenoxytetrahydrofuran-3-yl}propane-2-sulfonamide;
2-cyano-4\u2032-({(1R,2S)-2-(isopropyl sulfonyl)aminocyclopentyl}oxy)biphenyl-4-carboxylic acid;
N-{(1S,2R)-2-(2\u2032-cyano-2,4\u2032-difluorobiphenyl-4-yl)oxycyclopentyl}propane-2-sulfonamide;
N-{(1S,2R)-2-(2\u2032-ethoxy-2-fluorobiphenyl-4-yl)oxycyclopentyl}propane-2-sulfonamide;
N-{(1S,2R)-2-4-(5-cyano-2-thienyl)-3-fluorophenoxycyclopentyl}propane-2-sulfonamide;
N-{(1S,2R)-2-(2\u2032-cyano-2-fluorobiphenyl-4-yl)oxycyclohexyl}propane-2-sulfonamide;
N-{(1S,2R)-2-(2\u2032-cyano-2,4\u2032-difluorobiphenyl-4-yl)oxycyclohexyl}propane-2-sulfonamide;
N-{(1S,2R)-2-4-(5-cyano-2-thienyl)-3-fluorophenoxycyclohexyl}propane-2-sulfonamide;
N-(1S,2R)-2-(4-pyrrolidin-1-ylphenoxy)cyclohexylpropane-2-sulfonamide;
N-(1S,2R)-2-({6-2-(2,2,2-trifluoroethoxy)phenylpyridin-3-yl}oxy)cyclohexylpropane-2-sulfonamide;
N-(1S,2R)-2-({6-2-(trifluoromethoxy)phenylpyridin-3-yl}oxy)cyclohexylpropane-2-sulfonamide; or
N-(1S,2R)-2-{6-(5-cyano-2-thienyl)pyridin-3-yloxy}cyclohexylpropane-2-sulfonamide
or a pharmaceutically acceptable salt thereof.
31. A method for the treatment or prevention in a mammal of a condition selected from the group consisting of acute neurological and psychiatric disorders, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia, Alzheimer’s disease, Huntington’s Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson’s disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, migraine, urinary incontinence, substance tolerance, substance withdrawal, psychosis, schizophrenia, anxiety, mood disorders, trigeminal neuralgia, hearing loss, tinnitus, macular degeneration of the eye, emesis, brain edema, pain, tardive dyskinesia, sleep disorders, attention deficithyperactivity disorder, attention deficit disorder, and conduct disorder, comprising administering a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to the mammal.
32. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.